Subscriber access provided by AZ Library Organic Process Research & Development is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Article Mechanism and Processing Parameters Affecting the Formation of Methyl Methanesulfonate from Methanol and Methanesulfonic Acid: An Illustrative Example for Sulfonate Ester Impurity Formation Andrew Teasdale, Stephen C. Eyley, Ed Delaney, Karine Jacq, Karen Taylor-Worth, Andrew Lipczynski, Van Reif, David P. Elder, Kevin L. Facchine, Simon Golec, Rolf Schulte Oestrich, Pat Sandra, and Frank David Org. Process Res. Dev., Article ASAP • DOI: 10.1021/op8 00192a Downloaded from http://pubs.acs.org on January 22, 2009 More About This Article Additional resources and features associated with this article are available within the HTML version: • Supporting Information • Access to hi gh resolu ti on fi gures • Li nk s to art icles and content r el at ed to this ar tic le • Cop yri ght per mis sion t o r epr odu ce f igu res and /or tex t fr om thi s arti cle
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Organic Process Research & Development is published by the American Chemical
Society. 1155 Sixteenth Street N.W., Washington, DC 20036
Article
Mechanism and Processing Parameters Affecting the Formationof Methyl Methanesulfonate from Methanol and MethanesulfonicAcid: An Illustrative Example for Sulfonate Ester Impurity Formation
Andrew Teasdale, Stephen C. Eyley, Ed Delaney, Karine Jacq, KarenTaylor-Worth, Andrew Lipczynski, Van Reif, David P. Elder, Kevin L.
Facchine, Simon Golec, Rolf Schulte Oestrich, Pat Sandra, and Frank David
Org. Process Res. Dev., Article ASAP • DOI: 10.1021/op800192a
Downloaded from http://pubs.acs.org on January 22, 2009
More About This Article
Additional resources and features associated with this article are available within the HTML version:
• Supporting Information• Access to high resolution figures• Links to articles and content related to this article• Copyright permission to reproduce figures and/or text from this article
Mechanism and Processing Parameters Affecting the Formation of MethylMethanesulfonate from Methanol and Methanesulfonic Acid: An Illustrative Examplefor Sulfonate Ester Impurity Formation
Andrew Teasdale,*,† Stephen C. Eyley,*,† Ed Delaney,‡ Karine Jacq,§ Karen Taylor-Worth,⊥ Andrew Lipczynski,⊥ Van Reif, ¶
David P. Elder,0 Kevin L. Facchine,b Simon Golec,4 Rolf Schulte Oestrich,1 Pat Sandra,§ and Frank David§
AstraZeneca, R&D Charnwood, Bakewell Road, Loughborough, Leicestershire LE11 5RH, United Kingdom, Reaction Science Consulting, LLC, Suite 202/11 Deer Park DriVe, Monmouth Junction, New Jersey 08852, U.S.A., Research Institute for Chromatography, Pres. Kennedypark 26, B-8500, Kortrijk, Belgium, Pfizer Global Researchand DeVelopment, Analytical R&D, Ramsgate Road, Sandwich, Kent CT13 9NJ, United Kingdom, Schering-Plough,556 Morris AVenue, Summit, New Jersey 07901-1330, U.S.A., GlaxoSmithKline, Park Road, Ware, HertfordshireSG12 0DP, United Kingdom, GlaxoSmithKline, FiVe Moore DriVe, Research Triangle Park, North Carolina27709-3398, U.S.A., Wyeth Research, 500 Arcola Road, CollegeVille, PennsylVania 19426, U.S.A., and F.
† AstraZeneca, R&D.‡ Reaction Science Consulting, LLC.§ Research Institute for Chromatography.⊥ Pfizer Global Research and Development, Analytical R&D.
(1) Mesylate Ester Type Impurities Contained in Medicinal Products,Swissmedic Department for Control of the Medicinal Products Market,October 23, 2007.
(2) Coordination Group for Mutual Recognition-Human committee (CMDh),Request to Assess the Risk of Occurrence of Contamination withMesilate Esters and Other Related Compounds in Pharmaceutical,EMEA/CMDh/ 98694/2008, London, February 27, 2008.
(3) Winstein, S.; Grunwald, E.; Jones, H. W. J. Am. Chem. Soc. 1951,73, 2700.
(4) Robertson, R. E. Can. J. Chem. 1953, 31, 589.(5) Smith, M. B.; March, J. March’s Ad Vanced Organic Chemistry; Wiley:
New York, 2001; p 464.(6) Isaacs, N. Physical Organic Chemistry; Prentice Hall: Harlow, 1995;
p 418.(7) Bentley, T. W.; Bowen, C. T.; Brown, H. C.; Chloupek, F. J. J. Org.
Chem. 1981, 46 , 38.(8) Snodin, D. J. Regul. Toxicol. Pharmacol. 2006, 45, 79.(9) Padmapriya, A. A.; Just, G.; Lewis, N. G. Synth. Commun. 1985, 15,
1057.(10) Golborn, P. Synth. Commun. 1973, 3, 273.
Organic Process Research & Development XXXX, xxx, 000
10.1021/op800192a CCC: $40.75 XXXX American Chemical Society Vol. xxx, No. xx, XXXX / Organic Process Research & Development • A
(15) Chan, L. C.; Cox, B. G.; Sinclair, R. S. Org. Process Res.DeV. 2008,12, 213.
(16) Rived, F.; Roses, M.; Bosch, E. Anal. Chim. Acta 1998, 374, 309.
Figure 4. Effect of partial neutralisation of methanesulfonicacid on the formation of methyl methanesulfonate from the acidin methanol, as a function of temperature.
Figure 5. Solvolysis of methyl methanesulfonate in methanolicsolution.
D • Vol. xxx, No. xx, XXXX / Organic Process Research & Development
not catalyze a meaningful rate of ester formation at this level
of detection. These data therefore provide some quantitative
refinement to a qualitative discussion of the likelihood of
sulfonate ester formation.8
The overall rates of sulfonate ester formation, and hence
amounts of sulfonate ester formed, have been shown to be
reduced in the presence of water. This can be rationalized by
the competing solvation of proton by water compared with
methanol thereby reducing the rate of the forward reaction, and
by enhanced rate of hydrolysis of methyl methanesulfonate, asshown by the solvolysis data. The solvolytic data suggests that
the solvolysis may be neither acid-catalyzed nor base-induced
at the concentrations studied, (or that, by chance, the effects
are equal under the conditions studied).
These experimental data relate directly to the formation of
MMS ester in reaction mixtures, and not to isolated salts. They
therefore give guidance on upper limits anticipated for this
sulfonate ester prior to API salt isolation. Crystallization
processes to isolate API sulfonate salts upgrade purity through
rejection of impurities from the growing crystals. Consequently,
these experimental data also provide estimates of the upper
limits for sulfonate ester expected in crystallization liquors fromAPI salt formation processes. This understanding can serve as
the basis for planning experiments to demonstrate the efficien-
cies of discrimination against sulfonate esters during isolation
procedures for particular APIs. Selection of reaction conditions
to minimize ester formation and purification during isolation
can ensure the development of robust processes that will provide
material to meet API quality attributes relating to PGIs.
ConclusionsEvidence for the mechanism of formation of methyl meth-
anesulfonate from methanesulfonic acid and methanol was
attained. Studies of reaction profiles have quantified the levels
of sulfonate ester formed under conditions relevant to theformation of methanesulfonate salts of pharmaceutically active
bases. These studies demonstrate a clear scope to select
conditions for the preparation of sulfonate salts in alcoholic
solutions to minimize formation of sulfonate esters in reaction
mixtures relevant to API salt formation, by the following:
• reducing time-temperature envelopes for solutions of sulfonic acids in alcohols• incorporation of water into the process• reducing or eliminating the excesses of sulfonic acid usedin API salt formation
Of these, the most significant finding relates to the control
that can be achieved through the stoichiometric level of acid
used. When a slight excess of base is present, there is no
discernible reaction rate to form the sulfonate ester and no
mechanistic pathway to their formation.
An extended evaluation of the formation of other pharma-
ceutically relevant sulfonate esters from representative alcohols
and sulfonic acids will be discussed in a future publication,
which will also address the observed kinetics in greater detail.
AcknowledgmentWe thank the Product Quality Research Institute (PQRI),
and the member companies for their financial support in
realizing this project. Part of this work was presented at the
PhRMA API Conference, Puerto Rico, April 2008, and at